EL7.AI
StocksUpdated×2•Originally published 27 April 2026•Updated 28 April 2026•
1 min read

BNP Paribas Exane Cuts Equifax Price Target to $195 Following Insider Sales

Key Facts

1BNP Paribas Exane analysts lowered their price target for Equifax to $195.00 from $210.00 while maintaining a neutral rating.
2The company beat Q1 2026 earnings estimates despite the price target reduction.
3Insider selling was noted, involving the CEO and Executive Vice President.

BNP Paribas Exane analysts have lowered their price target for Equifax (EFX) to $195.00 from $210.00, maintaining a neutral rating. This adjustment follows news that CEO Mark W. Begor sold shares totaling approximately $6.52 million on April 24th, a move that reduced his direct stake in the company by 12.21%. Notably, the sales were executed under a pre-scheduled Rule 10b5-1 trading plan, suggesting the divestment was planned well in advance. In a positive move for investors, Equifax recently raised its quarterly dividend, signaling confidence in its long-term cash flow. While the company exceeded its Q1 2026 earnings estimates, the lowered price target reflects a cautious stance from analysts. Investors are currently weighing the impact of these executive sales against the company's fundamental growth and increased shareholder returns.